EP1750513A4 - Use of gpcr54 ligands for the treatment of infertility - Google Patents

Use of gpcr54 ligands for the treatment of infertility

Info

Publication number
EP1750513A4
EP1750513A4 EP05804783A EP05804783A EP1750513A4 EP 1750513 A4 EP1750513 A4 EP 1750513A4 EP 05804783 A EP05804783 A EP 05804783A EP 05804783 A EP05804783 A EP 05804783A EP 1750513 A4 EP1750513 A4 EP 1750513A4
Authority
EP
European Patent Office
Prior art keywords
gpcr54
infertility
ligands
treatment
gpcr54 ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05804783A
Other languages
German (de)
French (fr)
Other versions
EP1750513A2 (en
Inventor
Robert K Campbell
Xuliang Jiang
Shoji Nagatani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Publication of EP1750513A2 publication Critical patent/EP1750513A2/en
Publication of EP1750513A4 publication Critical patent/EP1750513A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05804783A 2004-04-23 2005-04-19 Use of gpcr54 ligands for the treatment of infertility Withdrawn EP1750513A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56475604P 2004-04-23 2004-04-23
PCT/US2005/013339 WO2005117939A2 (en) 2004-04-23 2005-04-19 Use of gpcr54 ligands for the treatment of infertility

Publications (2)

Publication Number Publication Date
EP1750513A2 EP1750513A2 (en) 2007-02-14
EP1750513A4 true EP1750513A4 (en) 2009-07-22

Family

ID=35463344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05804783A Withdrawn EP1750513A4 (en) 2004-04-23 2005-04-19 Use of gpcr54 ligands for the treatment of infertility

Country Status (7)

Country Link
EP (1) EP1750513A4 (en)
JP (1) JP2007533748A (en)
AU (1) AU2005249373A1 (en)
CA (1) CA2562676A1 (en)
IL (1) IL178795A0 (en)
NO (1) NO20065297L (en)
WO (1) WO2005117939A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571420A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (en) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co Metastin Derivatives And Use Thereof
RU2010114039A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) USE OF OCTREOTIDE AS A THERAPEUTIC
GB0719592D0 (en) 2007-10-08 2007-11-14 Medical Res Council Compound, use and method
LT2314609T (en) * 2008-07-30 2017-04-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
US9127038B2 (en) 2011-08-04 2015-09-08 Merck Sharp & Dohme Corp. Kisspeptide-pentasaccharide conjugates
WO2013142408A1 (en) * 2012-03-20 2013-09-26 Monell Chemical Senses Center Method of modifying fertility
FR3001455B1 (en) * 2013-01-31 2017-10-06 Agronomique Inst Nat Rech AGONIST COMPOUNDS OF THE KISS1R RECEPTOR AND THEIR USE IN INDUCING OVULATION IN MAMMALS
TW201605907A (en) * 2014-08-12 2016-02-16 國立臺灣大學 Use of a short-chain peptide capable of controlling spermatozoa fertilization performance to increasing success rates of in vitro fertilization
TWI778979B (en) * 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 Methods of treating female infertility
CN109125307B (en) * 2018-09-03 2021-05-07 河南牧翔动物药业有限公司 Clomidinol-polypeptide compound, pharmaceutical preparation, and preparation methods and applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (en) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2004080479A1 (en) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited Gonadal function improving agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (en) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2004080479A1 (en) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited Gonadal function improving agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DE ROUX NICOLAS ET AL: "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 19, 16 September 2003 (2003-09-16), pages 10972 - 10976, XP002531374, ISSN: 0027-8424 *
FUNES S ET AL: "The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 312, no. 4, 26 December 2003 (2003-12-26), pages 1357 - 1363, XP004476427, ISSN: 0006-291X *
GOTTSCH M L ET AL: "A ROLE FOR KISSPEPTINS IN THE REGULATION OF GONADOTROPIN SECRETION IN THE MOUSE", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 145, no. 9, 24 June 2004 (2004-06-24), pages 4073 - 4077, XP009052892, ISSN: 0013-7227 *
KOTANI M ET AL: "The Metastasis Suppressor Gene KiSS-1 Encodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54", JOURNAL OF BIOLOGICAL CHEMISTRY 20010914 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, vol. 276, no. 37, 14 September 2001 (2001-09-14), pages 34631 - 34636, XP002531375 *
MESSAGER SOPHIE ET AL: "Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 5, 1 February 2005 (2005-02-01), pages 1761 - 1766, XP002531376, ISSN: 0027-8424 *
NAVARRO V M ET AL: "Effects of KiSS-1 Peptide, the Natural Ligand of GPR54, on Follicle-Stimulating Hormone Secretion in the Rat", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 146, no. 4, 1 April 2005 (2005-04-01), pages 1689 - 1697, XP008091360, ISSN: 0013-7227 *
SEMINARA S B ET AL: "The GPR54 gene as a regulator of puberty", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 349, no. 17, 23 October 2003 (2003-10-23), pages 1614 - 1627, XP009021628, ISSN: 0028-4793 *

Also Published As

Publication number Publication date
WO2005117939A9 (en) 2006-04-20
AU2005249373A1 (en) 2005-12-15
NO20065297L (en) 2006-11-17
WO2005117939A2 (en) 2005-12-15
IL178795A0 (en) 2007-03-08
CA2562676A1 (en) 2005-12-15
WO2005117939A3 (en) 2006-06-01
EP1750513A2 (en) 2007-02-14
JP2007533748A (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EP1750513A4 (en) Use of gpcr54 ligands for the treatment of infertility
HK1203055A1 (en) Treatment for multiple sclerosis
EP1744751A4 (en) Methods for the treatment of synucleinopathies
SI3424932T1 (en) Boronophthalides for therapeutic use
EP1809265A4 (en) Methods for the treatment of synucleinopathies
EP1830847A4 (en) Treatment for cancer
IL183780A0 (en) Compounds for flaviviridae treatment
EP1832861A4 (en) Component for preanalytical treatment
EP1732549A4 (en) Methods for the treatment of synucleinopathies
PL377464A1 (en) Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
GB2430002B (en) Well treatment
GB0525540D0 (en) New treatment
HK1097247A1 (en) Process for the treatment of sludge
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0400802D0 (en) Compounds for the treatment of disease
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0426141D0 (en) Treatment
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
GB0424085D0 (en) Well treatment
ZA200606780B (en) Compounds for the treatment of diseases
GB0407354D0 (en) Treatment apparatus
SI1535612T1 (en) Treatment for hyperuricemia
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATOIRES SERONO SA

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 37/18 20060101ALI20071214BHEP

Ipc: A01N 61/00 20060101ALI20071214BHEP

Ipc: A61K 38/17 20060101AFI20071214BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090922